Previous close | 14.00 |
Open | 14.65 |
Bid | 14.90 |
Ask | 15.80 |
Strike | 160.00 |
Expiry date | 2024-01-19 |
Day's range | 14.65 - 15.45 |
Contract range | N/A |
Volume | |
Open interest | 395 |
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
AbbVie today shared findings from the newly launched Emotional Impact Report, a survey of more than 300 chronic lymphocytic leukemia (CLL) patients, caregivers and healthcare providers (HCPs), which uncovered insights about the emotional journey associated with a CLL diagnosis.
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.